全文获取类型
收费全文 | 128622篇 |
免费 | 11510篇 |
国内免费 | 6599篇 |
专业分类
耳鼻咽喉 | 1224篇 |
儿科学 | 1960篇 |
妇产科学 | 2934篇 |
基础医学 | 13452篇 |
口腔科学 | 2678篇 |
临床医学 | 15982篇 |
内科学 | 20165篇 |
皮肤病学 | 1590篇 |
神经病学 | 6391篇 |
特种医学 | 4195篇 |
外国民族医学 | 40篇 |
外科学 | 13340篇 |
综合类 | 19307篇 |
现状与发展 | 20篇 |
一般理论 | 18篇 |
预防医学 | 9462篇 |
眼科学 | 3444篇 |
药学 | 13457篇 |
114篇 | |
中国医学 | 6538篇 |
肿瘤学 | 10420篇 |
出版年
2024年 | 345篇 |
2023年 | 1712篇 |
2022年 | 4011篇 |
2021年 | 5426篇 |
2020年 | 4054篇 |
2019年 | 3666篇 |
2018年 | 3940篇 |
2017年 | 3706篇 |
2016年 | 3308篇 |
2015年 | 5235篇 |
2014年 | 6733篇 |
2013年 | 6950篇 |
2012年 | 10127篇 |
2011年 | 10875篇 |
2010年 | 7482篇 |
2009年 | 6150篇 |
2008年 | 7787篇 |
2007年 | 7728篇 |
2006年 | 7321篇 |
2005年 | 6692篇 |
2004年 | 4842篇 |
2003年 | 4405篇 |
2002年 | 3657篇 |
2001年 | 3092篇 |
2000年 | 2850篇 |
1999年 | 2648篇 |
1998年 | 1311篇 |
1997年 | 1223篇 |
1996年 | 986篇 |
1995年 | 949篇 |
1994年 | 885篇 |
1993年 | 505篇 |
1992年 | 894篇 |
1991年 | 803篇 |
1990年 | 671篇 |
1989年 | 573篇 |
1988年 | 526篇 |
1987年 | 450篇 |
1986年 | 358篇 |
1985年 | 284篇 |
1984年 | 186篇 |
1983年 | 169篇 |
1982年 | 95篇 |
1981年 | 93篇 |
1979年 | 141篇 |
1978年 | 111篇 |
1977年 | 83篇 |
1974年 | 94篇 |
1973年 | 72篇 |
1972年 | 87篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
25.
26.
目的探讨高血压合并脑卒中患者的血浆同型半胱氨酸(Hcy)水平与其他危险因素对于脑卒中复发的影响。
方法分析徐州市中心医院心内科和徐州医科大学附属医院神经外科自2012年5月至2013年12月收治的1623例高血压脑卒中患者的基线资料,中位随访4.9年,根据随访事件中是否发生脑卒中分为复发组(312例)与未复发组(1311例)。Kaplan-Meier生存分析比较不同危险因素脑卒中复发率的差异,单因素与多因素Cox回归模型分析影响脑卒中复发的独立危险因素,以及危险因素之间的交互作用。
结果复发组年龄、空腹血糖、Lg Hcy的水平,以及糖尿病、房颤的患病率均高于未复发组(P<0.05)。Kaplan-Meier生存分析显示,糖尿病、房颤、年龄≥60岁、空腹血糖≥7.0 mmol/L、Hcy≥15 μmol/L的脑卒中复发率明显升高(Log-rank检验,P<0.05)。多因素Cox回归模型分析显示,高龄、Lg Hcy水平升高,以及房颤、糖尿病是脑卒中复发的独立危险因素。Lg Hcy分别与糖尿病、空腹血糖、年龄存在交互作用。
结论血浆Hcy水平升高既是高血压合并脑卒中患者卒中复发的独立危险因素,又通过与糖尿病、高龄、空腹血糖水平升高的交互作用显著增加脑卒中复发风险。 相似文献
27.
It is hypothesized that persons who use drugs (PWUD) in Vietnam who are also HIV-positive may face additional challenges in psychosocial outcomes, and these challenges may extend to their family members. In this study, we examined depressive symptoms, stigma, social support, and caregiver burden of HIV-positive PWUD and their family members, compared to the outcomes of HIV-negative PWUD and their family members. Baseline, 3-month, and 6-month assessment data were gathered from 83 PWUD and 83 family members recruited from four communes in Phú Th? Province, Vietnam. For PWUD, although we observed a general decline in overall stigma over time for both groups, HIV-positive PWUD consistently reported significantly higher overall stigma for all three periods. Depressive symptoms among family members in both groups declined over time; however, family members of HIV-positive PWUD reported higher depressive symptoms across all three periods. In addition, family members of HIV-positive PWUD reported lower levels of tangible support across all three periods. Caregiver burden among family members of HIV-positive PWUD increased significantly over time, whereas the reported burden among family members of HIV-negative PWUD remained relatively unchanged. The findings highlight the need for future interventions for PWUD and family members, with targeted and culturally specific strategies to focus on the importance of addressing additional stigma experienced by PWUD who are HIV-positive. Such challenges may have direct negative impact on their family members' depressive symptoms, tangible support, and caregiver burden. 相似文献
28.
29.